{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:14:58Z","timestamp":1789139698305,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japanese Foundation for Cancer Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00428-024-04009-x","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T02:26:19Z","timestamp":1734575179000},"page":"983-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma\/paraganglioma"],"prefix":"10.1007","volume":"486","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2032","authenticated-orcid":false,"given":"Akihiro","family":"Ohmoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Inamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"4009_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L et al (2017) RARECAREnet working group. Burden and centralised treatment in Europe of rare tumours results of RARECAREnet-a population-based study. Lancet Oncol 18:1022\u20131039","journal-title":"Lancet Oncol"},{"key":"4009_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:1476\u20131490","journal-title":"Ann Oncol"},{"key":"4009_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","volume":"109","author":"SD Averbuch","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC et al (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109:267\u2013273","journal-title":"Ann Intern Med"},{"key":"4009_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT et al (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol 81:642\u2013651","journal-title":"Clin Endocrinol"},{"key":"4009_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1002\/cncr.23812","volume":"113","author":"H Huang","year":"2008","unstructured":"Huang H, Abraham J, Hung E et al (2008) Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020\u20132028","journal-title":"Cancer"},{"key":"4009_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","volume":"403","author":"E Baudin","year":"2024","unstructured":"Baudin E, Goichot B, Berruti A et al (2024) Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 403:1061\u20131070","journal-title":"Lancet"},{"key":"4009_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31:181\u2013193","journal-title":"Cancer Cell"},{"key":"4009_CR8","doi-asserted-by":"publisher","first-page":"8812","DOI":"10.1200\/JCO.2005.03.1484","volume":"23","author":"L Amar","year":"2005","unstructured":"Amar L, Bertherat J, Baudin E et al (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:8812\u20138818","journal-title":"J Clin Oncol"},{"key":"4009_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.292.8.943","volume":"292","author":"HP Neumann","year":"2004","unstructured":"Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943\u2013951","journal-title":"JAMA"},{"key":"4009_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","volume":"20","author":"D Ta\u00efeb","year":"2024","unstructured":"Ta\u00efeb D, N\u00f6lting S, Perrier ND et al (2024) Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement. Nat Rev Endocrinol 20:168\u2013184","journal-title":"Nat Rev Endocrinol"},{"key":"4009_CR11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","volume":"10","author":"FH van Nederveen","year":"2009","unstructured":"van Nederveen FH, Gaal J, Favier J et al (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10:764\u2013771","journal-title":"Lancet Oncol"},{"key":"4009_CR12","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/PAS.0000000000001715","volume":"45","author":"O Mete","year":"2021","unstructured":"Mete O, Pakbaz S, Lerario AM et al (2021) Significance of alpha-inhibin expression in pheochromocytomas and paragangliomas. Am J Surg Pathol 45:1264\u20131273","journal-title":"Am J Surg Pathol"},{"key":"4009_CR13","doi-asserted-by":"publisher","first-page":"e000347","DOI":"10.1136\/jitc-2019-000347","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8:e000347","journal-title":"J Immunother Cancer"},{"key":"4009_CR14","first-page":"589","volume":"29","author":"N Tufton","year":"2022","unstructured":"Tufton N, Hearnden RJ, Berney DM et al (2022) The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. Endocr Relat Cancer 29:589\u2013598","journal-title":"Endocr Relat Cancer"},{"key":"4009_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/path.6026","volume":"259","author":"L Celada","year":"2023","unstructured":"Celada L, Cubiella T, San-Juan-Guardado J et al (2023) Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype. J Pathol 259:103\u2013114","journal-title":"J Pathol"},{"key":"4009_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1507\/endocrj.EJ20-0762","volume":"68","author":"Y Fujiwara","year":"2021","unstructured":"Fujiwara Y, Ohmoto A, Fukuda N et al (2021) Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. Endocr J 68:671\u2013681","journal-title":"Endocr J"},{"key":"4009_CR17","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.labinv.2023.100210","volume":"103","author":"A Yu","year":"2023","unstructured":"Yu A, Xu X, Pang Y et al (2023) PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma\/Paraganglioma. Lab Invest 103:100210","journal-title":"Lab Invest"},{"key":"4009_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N et al (2014) Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21:405\u2013414","journal-title":"Endocr Relat Cancer"},{"key":"4009_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/his.14204","volume":"77","author":"N Baniak","year":"2020","unstructured":"Baniak N, Flood TA, Buchanan M et al (2020) Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology 77:659\u2013666","journal-title":"Histopathology"},{"key":"4009_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00428-023-03568-9","volume":"483","author":"Y Shigematsu","year":"2023","unstructured":"Shigematsu Y, Amori G, Tanaka K et al (2023) MHC class I loss is associated with biliary\/progenitor cell features and \u201ccold\u201d tumor-immune microenvironment in hepatocellular carcinoma. Virchows Arch 483:177\u2013186","journal-title":"Virchows Arch"},{"key":"4009_CR21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550","journal-title":"Lancet"},{"key":"4009_CR22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1186\/s12885-018-4902-8","volume":"18","author":"Y Shigematsu","year":"2018","unstructured":"Shigematsu Y, Inamura K, Yamamoto N et al (2018) Impact of CDX2 expression status on the survival of patients after curative resection for colorectal cancer liver metastasis. BMC Cancer 18:980","journal-title":"BMC Cancer"},{"key":"4009_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00428-022-03318-3","volume":"481","author":"Y Shigematsu","year":"2022","unstructured":"Shigematsu Y, Amori G, Kanda H et al (2022) Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Arch 481:253\u2013263","journal-title":"Virchows Arch"},{"key":"4009_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"4009_CR25","doi-asserted-by":"publisher","first-page":"770958","DOI":"10.3389\/fonc.2022.770958","volume":"12","author":"H Li","year":"2022","unstructured":"Li H, Abbas KS, Abdelazeem B et al (2022) A Predictive nomogram for early death in pheochromocytoma and paraganglioma. Front Oncol 12:770958","journal-title":"Front Oncol"},{"key":"4009_CR26","doi-asserted-by":"publisher","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H et al (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12:e0187398","journal-title":"PLoS One"},{"key":"4009_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.humpath.2018.10.041","volume":"86","author":"D Guo","year":"2019","unstructured":"Guo D, Zhao X, Wang A et al (2019) PD-L1 expression and association with malignant behavior in pheochromocytomas\/paragangliomas. Hum Pathol 86:155\u2013162","journal-title":"Hum Pathol"},{"key":"4009_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","volume":"79","author":"S Ghosal","year":"2023","unstructured":"Ghosal S, Hadrava Vanova K et al (2023) Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis. Endocrine 79:171\u2013179","journal-title":"Endocrine"},{"key":"4009_CR29","doi-asserted-by":"publisher","first-page":"108875","DOI":"10.1016\/j.clim.2021.108875","volume":"232","author":"KK Goswami","year":"2021","unstructured":"Goswami KK, Bose A, Baral R (2021) Macrophages in tumor: An inflammatory perspective. Clin Immunol 232:108875","journal-title":"Clin Immunol"},{"key":"4009_CR30","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1038\/ncomms7140","volume":"6","author":"L Fishbein","year":"2015","unstructured":"Fishbein L, Khare S, Wubbenhorst B et al (2015) Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun 6:6140","journal-title":"Nat Commun"},{"key":"4009_CR31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","volume":"14","author":"B Calsina","year":"2023","unstructured":"Calsina B, Pi\u00f1eiro-Y\u00e1\u00f1ez E, Mart\u00ednez-Montes \u00c1M et al (2023) Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma. Nat Commun 14:1122","journal-title":"Nat Commun"},{"key":"4009_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-018-0263-8","volume":"25","author":"F D'Angelo","year":"2019","unstructured":"D\u2019Angelo F, Ceccarelli M, Tala, et al (2019) The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med 25:176\u2013187","journal-title":"Nat Med"},{"key":"4009_CR33","doi-asserted-by":"publisher","first-page":"e1005850","DOI":"10.1371\/journal.pgen.1005850","volume":"12","author":"N M\u00e4kinen","year":"2016","unstructured":"M\u00e4kinen N, Aavikko M, Heikkinen T et al (2016) Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12. PLoS Genet 12:e1005850","journal-title":"PLoS Genet"},{"key":"4009_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4149\/neo_2017_215","volume":"64","author":"T Vosecka","year":"2017","unstructured":"Vosecka T, Vicha A, Zelinka T et al (2017) Absence of BRAF mutation in pheochromocytoma and paraganglioma. Neoplasma 64:278\u2013282","journal-title":"Neoplasma"},{"key":"4009_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40364-022-00443-8","volume":"11","author":"Y Chen","year":"2023","unstructured":"Chen Y, Sun H, Deng Y et al (2023) The clinical and genomic distinctions of Class1\/2\/3 BRAF-mutant colorectal cancer and differential prognoses. Biomark Res 11:11","journal-title":"Biomark Res"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-04009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-04009-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-04009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:03:45Z","timestamp":1747839825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-04009-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4009"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-04009-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In compliance with ethical standards, our study involving human participants was conducted following the guidelines outlined in the Declaration of Helsinki. The research protocol was approved by the Institutional Review Board (IRB) of Cancer Institute, Japanese Foundation for Cancer Research (No. 2020-GA-1065). Despite the waiver of informed consent, all personal data were handled with strict confidentiality and in accordance with data protection regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}